Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs

Published:2023-11-10 Issue:32 Volume:41 Page:4968-4972
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Booth Christopher M.¹²³^ORCID,Eisenhauer Elizabeth A.²^ORCID,Gyawali Bishal¹²³^ORCID,Tannock Ian F.⁴^ORCID

Affiliation:

1. Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada

2. Department of Oncology, Queen's University, Kingston, Canada

3. Department of Public Health Sciences, Queen's University, Kingston, Canada

4. Division of Medical Oncology, Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.23.01423

Reference58 articles.

1. Progression-Free Survival: Meaningful or Simply Measurable?

2. Randomized Clinical Trials in the Era of Precision Oncology—The Role of End Points, Industry Funding, and Medical Writing Integrity—Reply

3. Evolution of the Randomized Controlled Trial in Oncology Over Three Decades

4. Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points

5. Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can Machine Learning Overcome the 95% Failure Rate and Reality that Only 30% of Approved Cancer Drugs Meaningfully Extend Patient Survival?;Journal of Medicinal Chemistry;2024-09-10

2. Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward;eClinicalMedicine;2024-09

3. Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trials;International Journal of Cancer;2024-08-13

4. Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials;Cancer Research Communications;2024-08-01

5. Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment;Journal of Hepatology;2024-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3